Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1345-1350

  Shintani, Michiko ^a   Urano, Makoto ^b   Takakuwa, Yasunari ^b   Kuroda, Makoto ^b   Kamoshida, Shingo ^a  

^a KOBE UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fluoropyrimidine; Immunohistochemistry; TAS 102; Thymidine kinase 1; Thymidylate synthase

Indexed keywords

FLUOROPYRIMIDINE; THYMIDINE KINASE 1; THYMIDYLATE SYNTHASE;

ARTICLE; ENZYME ANALYSIS; ENZYME SYNTHESIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA; UTERUS CARCINOMA;

EID: 77950815731     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000770     Document Type: Article

References (32)

1. Kit S: Thymidine kinase. Microbiol Sci 2: 369-375, 1985.
2. Sherley JL and Kelly TJ: Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350-8358, 1988.
3. Wang N, He Q, Skog S, Eriksson S and Tribukait B: Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 23: 11-19, 2001.
4. Mikulits W, Hengstschläger M, Sauer T, Wintersberger E and Müllner EW: Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem 271: 853-860, 1996.
5. Hallek M, Wanders L, Strohmeyer S and Emmerich B: Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65: 1-5, 1992.
6. Hannigan BM, Barnett YA, Armstrong DB, McKelvey-Martin VJ and McKenna PG: Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother 8: 189-197, 1993.
7. O'Neill KL, Buckwalter MR and Murray BK: Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Diagn 1: 428-433, 2001.
8. Wu J, Mao Y, He L, Wang N, Wu C, He Q and Skog S: A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinomas. Anticancer Res 20: 4815-4820, 2000.
9. Mao Y, Wu J, Wang N, He L, Wu C, He Q and Skog S: A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest 20: 922-931, 2002.
10. Malet-Martino M and Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT and S-1): A review. Oncologist 7: 288-323, 2002.
11. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
12. Chu E and Allegra CJ: Mechanisms of clinical resistance to 5-fluorouracil chemotherapy. Cancer Treat Res 87: 175-195, 1996.
13. INK4a, cyclindependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16INK4a-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol Int 54: 564-575, 2004.
14. INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol 34: 594-601, 2004.
15. Huang C, Liu D, Masuya D, et al: Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92: 1231-1239, 2005.
16. Hashimoto H, Ozeki Y, Sato M, et al: Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 106: 1595-1601, 2006.
17. Temmink OH, Emura T, de Bruin M, Fukushima M and Peters GJ: Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 98: 779-789, 2007.
18. Emura T, Nakagawa F, Fujioka A, Ohshimo H and Kitazato K: Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep 11: 381-387, 2004.
19. Konishi T, Miyama T, Sakamoto S, Hirata T, Mafune K, Hiraishi M and Idezuki Y: Activities of thymidylate synthetase and thymidine kinase in gastric cancer. Surg Oncol 1: 215-221, 1992.
20. Sakamoto S, Ebuchi M and Iwama T: Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours. Anticancer Res 13: 205-207, 1993.
21. Kamoshida S, Matsuoka H, Matsuyama A, Shimomura S, Maruta M and Tsutsumi Y: Reproducible and reliable immunohistochemical demonstration of thymidylate synthase in formalinfixed, paraffin-embedded section: application of antigen retrieval in EDTA solution. Acta Histochem Cytochem 36: 115-118, 2003.
22. Kamoshida S, Shiogama K, Shimomura R, et al: Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14: 1223-1230, 2005.
23. Chung YM, Park S, Park JK, Kim Y, Kang Y and Yoo YD: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159: 95-101, 2000.
24. Grem JL, Danenberg KD, Behan K, et al: Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 7: 999-1009, 2001.
25. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001.
26. Kralovánszky J, Köves I, Orosz Z, et al: Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. Oncology 62: 167-174, 2002.
27. Fanciullino R, Evrard A, Cuq P, et al: Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in vitro study. Anticancer Drugs 17: 463-470, 2006.
28. He Q, Mao Y, Wu J, et al: Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25: 945-953, 2004.
29. Brockenbrough JS, Morihara JK, Hawes SE, et al: Thymidine kinase 1 and thymidine phosphorylase expression in non-small cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem 57: 1087-1097, 2009.
30. Edler D, Hallström M, Ragnhammar P and Blomgren H: Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression. Anticancer Res 22: 3113-3116, 2002.
31. Le François BG, Maroun JA and Birnboim HC: Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4a but not E2F. Br J Cancer 97: 1242-1250, 2007.
32. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M and Danesi R: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5: 1387-1395, 2006.